Stevens-Johnson syndrome history and symptoms: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{AHS}} | {{CMG}}; {{AE}} {{AHS}} | ||
==Overview == | ==Overview == | ||
Patients with Stevens-Johnson Syndrome usually have a history of recent drug use within the last 2 months or some other inciting trigger like infection or vaccination. It starts with a | Patients with Stevens-Johnson Syndrome usually have a history of recent drug use within the last 2 months or some other inciting trigger like infection or vaccination. It starts with a flu-like illness followed by skin eruptions that involve trunk and extremities mainly. Skin involvement in SJS is always <10 percent of the body surface. Blisters, erosions, vesicles and [[bullae]] are seen along with confluent redness and sloughing of skin. Mucosal lesions can be seen in 2 or more surfaces and can involve eyes, oral mucosa, nasopharynx or genitals commonly<ref name="pmid211627212">{{cite journal| author=Harr T, French LE| title=Toxic epidermal necrolysis and Stevens-Johnson syndrome. | journal=Orphanet J Rare Dis | year= 2010 | volume= 5 | issue= | pages= 39 | pmid=21162721 | doi=10.1186/1750-1172-5-39 | pmc=3018455 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21162721 }}</ref>. | ||
==History and Symptoms== | ==History and Symptoms== | ||
===History=== | ===History=== | ||
Patients with SJS may have a positive history of: | Patients with SJS may have a positive history of: | ||
*Recent | *Recent drug use | ||
*Recent viral or bacterial infection | *Recent viral or bacterial infection | ||
*Active malignancy | *Active malignancy | ||
=== Symptoms === | === Symptoms === | ||
Symptoms usually start within 2 | Symptoms usually start within 2 months of starting a drug or other inciting trigger. | ||
* '''Prodome of | * '''Prodome of flu like symptoms 1-3 days before skin eruptions'''. May include | ||
** [[Fever]] | ** [[Fever]] | ||
** [[Sore throat]] | ** [[Sore throat]] | ||
| Line 25: | Line 25: | ||
* '''Skin lesions''' | * '''Skin lesions''' | ||
** Involve less than 10 percent of body surface | ** Involve less than 10 percent of body surface | ||
** Start as red or reddish blue macules/papules on trunk and extremities and later increase in size and coalesce | ** Start as red or reddish blue macules/ papules on trunk and extremities and later increase in size and coalesce | ||
** Blisters/ | ** Blisters/erosions/bullae and vesicles are seen | ||
** Confluent redness with skin sloughing | ** Confluent redness with skin sloughing | ||
** Nikolsky Sign is Positive- which is the detachment of superficial epidermis on gentle pressure or rubbing of skin | ** Nikolsky Sign is Positive- which is the detachment of superficial epidermis on gentle pressure or rubbing of skin | ||
Latest revision as of 15:23, 15 September 2018
|
Stevens-Johnson syndrome Microchapters |
|
Differentiating Stevens-Johnson Syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Stevens-Johnson syndrome history and symptoms On the Web |
|
American Roentgen Ray Society Images of Stevens-Johnson syndrome history and symptoms |
|
Risk calculators and risk factors for Stevens-Johnson syndrome history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2]
Overview
Patients with Stevens-Johnson Syndrome usually have a history of recent drug use within the last 2 months or some other inciting trigger like infection or vaccination. It starts with a flu-like illness followed by skin eruptions that involve trunk and extremities mainly. Skin involvement in SJS is always <10 percent of the body surface. Blisters, erosions, vesicles and bullae are seen along with confluent redness and sloughing of skin. Mucosal lesions can be seen in 2 or more surfaces and can involve eyes, oral mucosa, nasopharynx or genitals commonly[1].
History and Symptoms
History
Patients with SJS may have a positive history of:
- Recent drug use
- Recent viral or bacterial infection
- Active malignancy
Symptoms
Symptoms usually start within 2 months of starting a drug or other inciting trigger.
- Prodome of flu like symptoms 1-3 days before skin eruptions. May include
- Skin lesions
- Involve less than 10 percent of body surface
- Start as red or reddish blue macules/ papules on trunk and extremities and later increase in size and coalesce
- Blisters/erosions/bullae and vesicles are seen
- Confluent redness with skin sloughing
- Nikolsky Sign is Positive- which is the detachment of superficial epidermis on gentle pressure or rubbing of skin
- Target lesions are not typically seen (as opposed to Erythema Multiforme)
- Mucosal Lesions
- Can be seen before or after the skin eruptions
- Can involve 2 or more mucosal surfaces
- Seen in 90 percent of cases of SJS/TEN[2]
- Involved mucosal surfaces may include[3]
- Buccal mucosa: Painful erosions leading to Stomatitis and Mucositis
- Ocular: Seen frequently and range from acute conjuctivitis, eyelid edema and erythema, crusting, ocular discharge, Corneal erosion to corneal ulceration[4]
- Urogenital : Can cause Urethritis, Vulvovaginitis
- Nasopharynx
- Tracheo-Bronchial and intestinal involvement is uncommon[5]
References
- ↑ Harr T, French LE (2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet J Rare Dis. 5: 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.
- ↑ Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS (2005). "Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature". Ann Allergy Asthma Immunol. 94 (4): 419–36, quiz 436-8, 456. doi:10.1016/S1081-1206(10)61112-X. PMID 15875523.
- ↑ Harr T, French LE (2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet J Rare Dis. 5: 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.
- ↑ Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z; et al. (2009). "Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications". Ophthalmology. 116 (4): 685–90. doi:10.1016/j.ophtha.2008.12.048. PMID 19243825.
- ↑ Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C; et al. (1997). "Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study". Intensive Care Med. 23 (12): 1237–44. PMID 9470079.